А.E. Bаgrii, Ye.Ye. Kоvyrshinа, О.V. Sаmоilоvа, Ye.V. Shchukina, S.I. Mаlоvichkо Dronedarone in patients with atrial fibrillation after PALLAS study.

The article presents data regarding role of dronedarone in cardiology practice after the PALLAS study, as well as own data on the use of dronedarone in 13 patients with paroxysmal and persistent atrial fibrillation in the presence of chronic renal disease 1–2 stages over 12 weeks. Results of the PALLAS study demonstrate that usage of dronedarone in patients with paroxysmal / persistent atrial fibrillation is effective and safe. This does not apply to patients with permanent atrial fibrillation, as well as to patients with chronic heart failure and left ventricular ejection fraction less than 45%. The obtained experience of dronedarone usage shows its satisfactory tolerability, possibility of prevention of atrial fibrillation paroxysms, decrease of their duration and frequency of ventricular rate, as well as significant reduction of ventricular arrhythmia.

Full article